Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 14Terminated 5Active not recruiting 4Withdrawn 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Leukemia, Myeloid, Acute 38Breast Neoplasms 38Lymphoma, Large B-Cell, Diffuse 37Multiple Myeloma 31Lymphoma, Non-Hodgkin 30Burkitt Lymphoma 30Lymphoma 28Myelodysplastic Syndromes 25Triple Negative Breast Neoplasms 23Lymphoma, B-Cell 22Hematologic Neoplasms 22Recurrence 21Lymphoma, Follicular 20Melanoma 16Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Ovarian Neoplasms 13Neoplasm Metastasis 13Hodgkin Disease 13Neoplasms 12Leukemia, Biphenotypic, Acute 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Carcinoma, Non-Small-Cell Lung 10Sarcoma 9

Interventions

Carboplatin 18Paclitaxel 17Bevacizumab 17olaparib 8Specimen Handling 7liposomal doxorubicin 6pembrolizumab 5Taxes 5Biopsy 5cemiplimab 4Magnetic Resonance Spectroscopy 4sarilumab 3niraparib 3mirvetuximab soravtansine 3Topotecan 3Standard of Care 3Letrozole 3Gemcitabine 3Cisplatin 3130-nm albumin-bound paclitaxel 3taxane 2talazoparib 2palbociclib 2abemaciclib 2Temozolomide 2Surgical Procedures, Operative 2Practice Guidelines as Topic 2Poly(ADP-ribose) Polymerase Inhibitors 2Immunoglobulin G 2Fulvestrant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Fallopian Tube Neoplasms × Cyclophosphamide × Clear all
NCT06483048 2026-03-16

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer

Mayo Clinic

Phase 1 Recruiting
12 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡